Literature DB >> 19802369

Inherited predisposition to chronic lymphocytic leukemia.

Jennifer R Brown1.   

Abstract

Inherited susceptibility to chronic lymphocytic leukemia (CLL) has been recognized for decades. Approximately 10% of individuals with CLL report a family history of CLL or a related lymphoproliferative disorder, and genetic predisposition is the best understood risk factor for CLL. Studies of familial CLL have suggested that the disease features are largely similar to sporadic CLL, although recent data suggest that familial CLL may more commonly show somatic hypermutation of the immunoglobulin heavy-chain variable region, suggesting a more indolent disease course. Monoclonal B-cell lymphocytosis (MBL) has been identified recently as a likely precursor to CLL; it is found in the general population with increasing age and enriched in unaffected relatives of individuals with familial CLL. Studies of MBL as well as mouse models of CLL may lead to better understanding of early CLL pathogenesis that is relevant to familial predisposition. To date, the identification of genes that predispose to familial CLL has been slow, primarily due to the relatively few families available for study, the small size of those families and disease causation most likely by multiple genes that each confer smaller risks. In the coming years, the application of systematic genomics approaches to familial CLL should, hopefully, lead to the identification of novel loci involved in the disease.

Entities:  

Keywords:  association; familial chronic lymphocytic leukemia; linkage; lymphocytosis; monoclonal B cell

Mesh:

Substances:

Year:  2008        PMID: 19802369      PMCID: PMC2732130          DOI: 10.1586/17474086.1.1.51

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  112 in total

1.  Anticipation in familial chronic lymphocytic leukemia.

Authors:  L R Goldin; M Sgambati; G E Marti; L Fontaine; N Ishibe; N Caporaso
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia.

Authors:  S Bevan; D Catovsky; A Marossy; E Matutes; S Popat; P Antonovic; A Bell; A Berrebi; E Gaminara; K Quabeck; I Ribeiro; F R Mauro; P Stark; H Sykes; J van Dongen; J Wimperis; S Wright; M R Yuille; R S Houlston
Journal:  Leukemia       Date:  1999-10       Impact factor: 11.528

3.  Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia.

Authors:  J Demeter; F Porzsolt; S Rämisch; D Schmidt; M Schmid; G Messer
Journal:  Br J Haematol       Date:  1997-04       Impact factor: 6.998

4.  Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysis.

Authors:  B Summersgill; P Thornton; S Atkinson; E Matutes; J Shipley; D Catovsky; R S Houlston; M R Yuille
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

5.  CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not.

Authors:  Naoko Ishibe; Maher Albitar; Iman B Jilani; Lynn R Goldin; Gerald E Marti; Neil E Caporaso
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

6.  TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival.

Authors:  S Y Lee; A Reichlin; A Santana; K A Sokol; M C Nussenzweig; Y Choi
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

7.  Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.

Authors:  Andy C Rawstron; Martin R Yuille; Julie Fuller; Matthew Cullen; Ben Kennedy; Stephen J Richards; Andrew S Jack; Estella Matutes; Daniel Catovsky; Peter Hillmen; Richard S Houlston
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia.

Authors:  Naoko Ishibe; DaRue Prieto; Douglas A Hosack; Richard A Lempicki; Lynn R Goldin; Mark Raffeld; Gerald E Marti; Neil E Caporaso
Journal:  Leuk Res       Date:  2002-09       Impact factor: 3.156

9.  Anticipation in familial chronic lymphocytic leukaemia.

Authors:  M R Yuille; R S Houlston; D Catovsky
Journal:  Leukemia       Date:  1998-11       Impact factor: 11.528

10.  Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.

Authors:  Andy C Rawstron; Michael J Green; Anita Kuzmicki; Ben Kennedy; James A L Fenton; Paul A S Evans; Sheila J M O'Connor; Stephen J Richards; Gareth J Morgan; Andrew S Jack; Peter Hillmen
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

View more
  5 in total

1.  Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future.

Authors:  Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2013-08

2.  Prevalence of monoclonal B lymphocytosis in first-degree relatives of chronic lymphocytic leukemia patients in Turkey.

Authors:  Taner Demirci; Zeynep Arzu Yeğin; Nevruz Kurşunoğlu; Zeynep Yılmaz; Elif Suyanı; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Turk J Haematol       Date:  2015-03-05       Impact factor: 1.831

3.  The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.

Authors:  Antonella Nicolò; Alexandra Theresa Linder; Hassan Jumaa; Palash Chandra Maity
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

4.  p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.

Authors:  Nazanin Jalilian; Yosra Maleki; Ebrahim Shakiba; Mozafar Aznab; Ziba Rahimi; Mehdi Salimi; Zohreh Rhimi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01

Review 5.  Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics.

Authors:  Dan A Landau; Catherine J Wu
Journal:  Genome Med       Date:  2013-05-29       Impact factor: 11.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.